Network metaanalysis and cost per responder of tumor necrosis factor, interleukin, and phosphodiesterase inhibitors in the treatment of psoriatic arthritis

被引：0
|
作者：
Strand, Vibeke [1 ]
Husni, M. Elaine [2 ]
Griffith, Jenny [3 ]
Betts, Keith [4 ]
Beppu, Marci [3 ]
Song, Yan [4 ]
Ganguli, Arijit [3 ]
机构：
[1] Stanford Univ, Palo Alto, CA 94304 USA
[2] Cleveland Clin, Cleveland, OH 44106 USA
[3] AbbVie Inc, N Chicago, IL USA
[4] Anal Grp Inc, Boston, MA USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2016年 / 74卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
2534
引用
收藏
页码：AB260 / AB260
页数：1
相关论文
共 50 条
  • [41] Tumor necrosis factor inhibitors for rheumatoid arthritis
    Scott, D. L.
    Kingsley, G. H.
    NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (07): : 704 - 712
  • [42] Secukinumab vs Adalimumab for the Treatment of Psoriatic Arthritis: A Cost per Responder Analysis at 48 Weeks from a Canadian Perspective
    Gladman, Dafna
    Nikoglou, Efthalia
    Gunda, Praveen
    Chiva-Razavi, Sima
    Jugl, Steffen
    JOURNAL OF RHEUMATOLOGY, 2017, 44 (06) : 924 - 924
  • [43] Tumor necrosis factor inhibitors for rheumatoid arthritis
    Jones, RE
    Moreland, LW
    BULLETIN ON THE RHEUMATIC DISEASES, 1999, 48 (03) : 1 - 4
  • [44] LONG TERM COSTS AND OUTCOMES IN PSORIATIC ARTHRITIS PATIENTS NOT RESPONDING TO CONVENTIONAL THERAPY TREATED WITH TUMOR NECROSIS FACTOR INHIBITORS: THE EXTENSION OF PSORIATIC ARTHRITIS COST EVALUATION (PACE) STUDY
    Cortesi, P. A.
    Olivieri, I
    de Portu, S.
    Salvarani, C.
    Cauli, A.
    Lubrano, E.
    Spadaro, A.
    Cantini, F.
    Cutro, M.
    Mathieu, A.
    Matucci-Cerinic, M.
    Pappone, N.
    Punzi, L.
    Scarpa, R.
    Mantovani, L. G.
    VALUE IN HEALTH, 2013, 16 (07) : A566 - A566
  • [45] The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy
    Olivieri, I.
    de Portu, S.
    Salvarani, C.
    Cauli, A.
    Lubrano, E.
    Spadaro, A.
    Cantini, F.
    Cutro, M. S.
    Mathieu, A.
    Matucci-Cerinic, M.
    Pappone, N.
    Punzi, L.
    Scarpa, R.
    Mantovani, L. G.
    RHEUMATOLOGY, 2008, 47 (11) : 1664 - 1670
  • [46] Role of Agents other than Tumor Necrosis Factor Blockers in the Treatment of Psoriatic Arthritis
    Atzeni, Fabiola
    Costa, Luisa
    Caso, Francesco
    Scarpa, Raffaele
    Sarzi-Puttini, Piercarlo
    JOURNAL OF RHEUMATOLOGY, 2015, 42 : 79 - 81
  • [47] New Approaches in Tumor Necrosis Factor Antagonism for the Treatment of Psoriatic Arthritis: Certolizumab Pegol
    Cauli, Alberto
    Piga, Matteo
    Lubrano, Ennio
    Marchesoni, Antonio
    Floris, Alberto
    Mathieu, Alessandro
    JOURNAL OF RHEUMATOLOGY, 2015, 42 : 70 - 72
  • [48] TUMOR NECROSIS FACTOR INHIBITOR TREATMENT IN PSORIATIC ARTHRITIS: NEED FOR CO-MEDICATION?
    Michelsen, B.
    Soldal, D. M.
    Kavanaugh, A.
    Boyle, D. L.
    Haugeberg, G.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 599 - 599
  • [49] Treatment of recalcitrant psoriatic arthritis with anti-tumor necrosis factor-α antibody
    Wollina, U
    Konrad, H
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2002, 16 (02) : 127 - 129
  • [50] Biarylcarboxamide inhibitors of phosphodiesterase IV and tumor necrosis factor.
    Chambers, RJ
    Antognoli, GW
    Cheng, JB
    Cohan, VL
    Duplantier, AJ
    Hibbs, TA
    Jenkinson, TH
    Johnson, KL
    Kraus, KG
    Marfat, A
    Pettipher, RE
    Salter, ED
    Shirley, JT
    Umland, JP
    Watson, JW
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1996, 212 : 139 - MEDI
12345